Redesigns development and manufacturing approach to support increasingly complex and fast-moving market needs.

Biologics technology transfer (tech transfer) requires close coordination across every step, from initial process definition, subsequent analytical interpretation, and cross-facility execution.

Pharmaceutical manufacturing steps are often isolated in space and time. The synthesis, isolation and purification of the drug substance (DS) and the formulation of the drug product (DP) may be ...

Theriva Biologics and the Universitat Autònoma de Barcelona to receive a total of €2.28 Million to support the THERICEL project, a suspension cell platform for manufacturing viral-based therapies ...

The acquisition will establish Zydus' presence in fast growing global biologics CDMO space. Acquired capabilities include cutting-edge biologics development and manufacturing services to serve the ...

INCHEON, South Korea, ROCKVILLE, Md. and LONDON , Dec. 21, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing ...

As biologics have increasingly superseded small molecules in the biopharma industry’s pipeline, the mounting complexity of their manufacturing products is putting production and launches under ...

Kyowa Kirin will invest up to $530M and create more than 100 jobs at its new biologics manufacturing plant in Sanford, NC. Kyowa Kirin, Inc. plans to invest up to $530 million to build a new, state-of ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences (Nasdaq: GILD) today celebrates the groundbreaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center ...

DUBLIN--(BUSINESS WIRE)--The "Biologics Contract Manufacturing Market Industry Trends and Global Forecasts to 2035, by Type of Service Offered, Type of Biologic Manufactured, Type of Expression System ...

Recent advances in subcutaneous delivery methods now enable patient self-delivery of monoclonal antibody (mAb) therapies. Subcutaneous therapies often require concentrations around 100 to 200 mg/mL.

Nucleus Biologics, a leading provider of custom cell culture solutions and manufacturing technologies for advanced therapies, today announced the launch of Krakatoa® K500, the first bioreactor-scale, ...